China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal...
VS-041, a novel and potentially life-saving treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology comp...
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivot...
Symbiosis Pharmaceutical Services Ltd (Symbiosis), a rapidly growing sterile biopharmaceutical Contract Manufacturing Organisation (CMO) announces the pu...
PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 years A proportion of patients remained insulin-independent for up t...
Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Resear...
Moderna, Inc. announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion r...
Orphan designation shows recognition of therapeutic potential of drug candidate SBL01 targeting two regulated cell death pathways European Medicines A...
Phase III V-MONO study met its primary endpoints, demonstrating superiority of Leqvio (inclisiran) monotherapy vs both placebo and ezetimibe in LDL-C r...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd , announced that the Company has sign...
PI-2620 is in Phase 3 development in Alzheimer’s disease by AC Immune’s partner, LMI This Fast Track designation applies across Al...
LIXTE Biotechnology Holdings, Inc. announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer In...
Moderna, Inc. announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial...
Successful launch of Bentrio by Pharma Nordic AS in Norway in 2024 Exclusive distribution agreement extended to also include Sweden and Denmark Alt...
© 2025 Biopharma Boardroom. All Rights Reserved.
